| Budget Amount *help |
¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
Fiscal Year 2014: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2013: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
|
|---|
| Outline of Final Research Achievements |
Castration Resistant Prostate Cancer (CRPC) comprises a large portion of cause of death among prostate cancer patients. In about 30% of CRPC cases, Prostate Specific Antigen (PSA), the most reliable marker for diagnosis and assessment of the therapeutic value, is not associated with the disease progression. As a result, developing a useful treatment in terms of the predictor of therapeutic value and prognosis was a pressing issue for us to be resolved.
We have been developing the photodynamic diagnosis (PDD) using patients’ urine for the detection of prostate cancer. In this study, PDD is applied to the diagnosis for CRPC. Namely, Protoporphyrin IX (PpIX) can be detected in CRPC patients’ urine and the intensity of PpIX can be quantified by the spectrophotometer. Moreover, the deletion of PTEN, which is known as the biomarker for the curative therapy such as radiation and operation, can be detected in CRPC patients’ urine by FISH. About 40 % of CPRC appeared PTEN deletion by FISH.
|
